Annie Brion

600 total citations
17 papers, 162 citations indexed

About

Annie Brion is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Annie Brion has authored 17 papers receiving a total of 162 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 8 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Annie Brion's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Annie Brion is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Annie Brion collaborates with scholars based in France and Switzerland. Annie Brion's co-authors include Éric Deconinck, Patrick Hervé, Jean‐Yves Cahn, E Racadot, Pierre Tiberghien, Bruno Lioure, Craig W. Reynolds, Pierre Bordigoni, Ya‐Wen Chiang and Dan L. Longo and has published in prestigious journals such as Blood, Medicine and Vaccine.

In The Last Decade

Annie Brion

17 papers receiving 161 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Annie Brion France 6 62 56 49 47 45 17 162
Krisztián Kállay Hungary 9 33 0.5× 28 0.5× 65 1.3× 25 0.5× 53 1.2× 27 196
Д. С. Абрамов Russia 7 23 0.4× 19 0.3× 46 0.9× 75 1.6× 58 1.3× 56 169
Deepika Bhatla United States 7 52 0.8× 31 0.6× 34 0.7× 10 0.2× 41 0.9× 9 199
Juliana Silva United Kingdom 5 34 0.5× 19 0.3× 63 1.3× 22 0.5× 45 1.0× 7 143
Caspar I. van der Made Netherlands 6 29 0.5× 93 1.7× 23 0.5× 16 0.3× 96 2.1× 13 292
Maria Faßhauer Germany 8 31 0.5× 97 1.7× 10 0.2× 38 0.8× 97 2.2× 24 192
Kohmei Kubo Japan 9 18 0.3× 24 0.4× 73 1.5× 19 0.4× 19 0.4× 19 178
Tiziana Coliva Italy 8 67 1.1× 60 1.1× 63 1.3× 30 0.6× 55 1.2× 11 309
Tomoharu Takeoka Japan 7 14 0.2× 25 0.4× 27 0.6× 34 0.7× 34 0.8× 14 185
Shinsuke Hirabayashi Japan 9 52 0.8× 43 0.8× 18 0.4× 14 0.3× 38 0.8× 28 220

Countries citing papers authored by Annie Brion

Since Specialization
Citations

This map shows the geographic impact of Annie Brion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Brion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Brion more than expected).

Fields of papers citing papers by Annie Brion

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annie Brion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Brion. The network helps show where Annie Brion may publish in the future.

Co-authorship network of co-authors of Annie Brion

This figure shows the co-authorship network connecting the top 25 collaborators of Annie Brion. A scholar is included among the top collaborators of Annie Brion based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Brion. Annie Brion is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Labreuche, Julien, Éric Durot, Cécile Tomowiak, et al.. (2022). Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia?. Hematological Oncology. 40(3). 400–408. 5 indexed citations
2.
Pierron, Alix, Ana Berceanu, Jean Fontan, et al.. (2021). Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?. Vaccine. 39(48). 7036–7043. 5 indexed citations
3.
Troude, P., et al.. (2020). Assessing the impact of a quality improvement program on the quality and timeliness of discharge documents. Medicine. 99(51). e23776–e23776. 3 indexed citations
4.
Roussel, Xavier, et al.. (2020). Pyogenic Granuloma During Ibrutinib Therapy for B-Cell Neoplasia. JCO Oncology Practice. 16(12). 834–836. 2 indexed citations
5.
Ysebaert, Loïc, Anne‐Sophie Michallet, Fontanet Bijou, et al.. (2019). Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients. Blood. 134(Supplement_1). 1741–1741. 2 indexed citations
6.
Protin, Caroline, Jehan Dupuis, Caroline Dartigeas, et al.. (2017). Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). American Journal of Hematology. 93(2). E52–E54. 2 indexed citations
7.
Meunier, Godelieve, Loïc Ysebaert, Phi‐Linh Nguyen‐Thi, et al.. (2016). First‐line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. Hematological Oncology. 35(4). 671–678. 4 indexed citations
8.
Fornecker, Luc‐Matthieu, Thérèse Aurran‐Schleinitz, Anne‐Sophie Michallet, et al.. (2015). Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience. American Journal of Hematology. 90(6). 511–514. 17 indexed citations
9.
Meunier, Godelieve, Loïc Ysebaert, Phi‐Linh Nguyen‐Thi, et al.. (2015). First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study. Blood. 126(23). 4170–4170. 1 indexed citations
10.
Clavert, Aline, Martine Gardembas, Martine Escoffre‐Barbe, et al.. (2014). A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma: The GOELAMS LCP 99 trial. American Journal of Hematology. 89(11). 1024–1029. 17 indexed citations
11.
Fornecker, Luc‐Matthieu, Thérèse Aurran‐Schleinitz, Anne‐Sophie Michallet, et al.. (2012). Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience. Blood. 120(21). 1796–1796. 2 indexed citations
12.
Brion, Annie, Faézeh Legrand, Fabrice Larosa, et al.. (2011). Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis. Investigational New Drugs. 30(4). 1697–1702. 2 indexed citations
13.
14.
Limat, Samuel, Philippe Fagnoni, Laurent Voillat, et al.. (2005). Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin???s Lymphoma. Clinical Drug Investigation. 25(11). 719–729. 6 indexed citations
15.
16.
17.
Delain, Martine, Jean‐Yves Cahn, E Racadot, et al.. (1993). Graft Failure after T Cell Depleted HLA Identical Allogeneic Bone Marrow Transplantation: Risk Factors in Leukemic Patients. Leukemia & lymphoma. 11(5-6). 359–368. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krisztián Kállay Breakdown of academic impact, for papers by Д. С. Абрамов Breakdown of academic impact, for papers by Deepika Bhatla Breakdown of academic impact, for papers by Juliana Silva Breakdown of academic impact, for papers by Caspar I. van der Made Breakdown of academic impact, for papers by Maria Faßhauer Breakdown of academic impact, for papers by Kohmei Kubo Breakdown of academic impact, for papers by Tiziana Coliva Breakdown of academic impact, for papers by Tomoharu Takeoka Breakdown of academic impact, for papers by Shinsuke Hirabayashi
Rankless by CCL
2026